AG˹ٷ

STOCK TITAN

[144] Ginkgo Bioworks Holdings, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Ginkgo Bioworks Holdings, Inc. (DNA) filed a Form 144 disclosing a planned disposition of 2,200 Class A shares (estimated value $31,020) through Fidelity Brokerage beginning on 08/06/2025. The shares, acquired via restricted-stock vesting on 10/17/2022, equal roughly 0.005% of the reported 46.34 million shares outstanding—an immaterial portion of DNA’s float.

The account holder, Austin Che, has already sold small 99-share lots over the last three months, totaling 3,366 shares for about $27 k plus a 2,200-share block on 07/09/2025 for $24.6 k. Form 144 requires the filer to certify no possession of undisclosed material information and, if relying on Rule 10b5-1, that a compliant trading plan exists. No operational, earnings, or strategic data accompany the notice; it solely signals modest insider liquidity. Given the limited size, analysts should expect negligible impact on DNA’s share supply or valuation.

Ginkgo Bioworks Holdings, Inc. (DNA) ha presentato un modulo Form 144 per comunicare una prevista cessione di 2.200 azioni di Classe A (valore stimato 31.020 dollari) tramite Fidelity Brokerage a partire dal 06/08/2025. Le azioni, ottenute con il vesting di azioni vincolate il 17/10/2022, rappresentano circa lo 0,005% delle 46,34 milioni di azioni in circolazione, una quota irrilevante del flottante di DNA.

Il titolare del conto, Austin Che, ha già venduto piccoli lotti da 99 azioni negli ultimi tre mesi, per un totale di 3.366 azioni per circa 27.000 dollari, oltre a un blocco di 2.200 azioni il 09/07/2025 per 24.600 dollari. Il modulo 144 richiede al dichiarante di certificare di non possedere informazioni materiali non divulgate e, se si basa sulla Regola 10b5-1, che esista un piano di trading conforme. Nessun dato operativo, sugli utili o strategico accompagna la comunicazione; segnala solo una modesta liquidità interna. Data la dimensione limitata, gli analisti dovrebbero aspettarsi un impatto trascurabile sull’offerta di azioni o sulla valutazione di DNA.

Ginkgo Bioworks Holdings, Inc. (DNA) presentó un Formulario 144 divulgando una disposición planificada de 2.200 acciones Clase A (valor estimado en $31,020) a través de Fidelity Brokerage a partir del 06/08/2025. Las acciones, adquiridas mediante vesting de acciones restringidas el 17/10/2022, representan aproximadamente el 0,005% de las 46,34 millones de acciones en circulación, una porción insignificante del flotante de DNA.

El titular de la cuenta, Austin Che, ya ha vendido pequeños lotes de 99 acciones en los últimos tres meses, totalizando 3.366 acciones por alrededor de $27,000, además de un bloque de 2.200 acciones el 09/07/2025 por $24,600. El Formulario 144 requiere que el declarante certifique no poseer información material no divulgada y, si se basa en la Regla 10b5-1, que exista un plan de trading conforme. No se acompañan datos operativos, de ganancias o estratégicos; solo señala una modesta liquidez interna. Dado el tamaño limitado, los analistas deberían esperar un impacto insignificante en la oferta de acciones o valoración de DNA.

Ginkgo Bioworks Holdings, Inc. (DNA)� 2025� 8� 6일부� Fidelity Brokerage� 통해 2,200� 클래� A 주식 (추정 가� 31,020달러)� 처분 계획� 공개하는 Form 144� 제출했습니다. � 주식들은 2022� 10� 17� 제한 주식 베스팅을 통해 취득� 것으�, � 4,634� � � � 0.005%� 해당하는 매우 미미� 규모입니�.

계좌 보유� Austin Che� 지� 3개월� 소규� 99� 단위� � 3,366�� � 27,000달러� 매도했으�, 2025� 7� 9일에� 2,200� 블록� � 24,600달러� 매도했습니다. Form 144� 신고자가 미공� 중요 정보� 보유하지 않았음을 증명하고, Rule 10b5-1� 의거� 경우 적법� 거래 계획� 있음� 확인하도� 요구합니�. 운영, 수익 또는 전략 관� 데이터는 포함되어 있지 않으�, 단지 소규� 내부 유동성을 알리� 공지입니�. 규모가 제한적이므� 애널리스트들은 DNA 주식 공급이나 가치에 거의 영향� 없을 �으로 예상해야 합니�.

Ginkgo Bioworks Holdings, Inc. (DNA) a déposé un formulaire 144 divulguant une cession prévue de 2 200 actions de classe A (valeur estimée à 31 020 $) via Fidelity Brokerage à partir du 06/08/2025. Les actions, acquises par acquisition d’actions restreintes le 17/10/2022, représentent environ 0,005 % des 46,34 millions d’actions en circulation, une part négligeable du flottant de DNA.

Le titulaire du compte, Austin Che, a déjà vendu de petits lots de 99 actions au cours des trois derniers mois, totalisant 3 366 actions pour environ 27 000 $, ainsi qu’un bloc de 2 200 actions le 09/07/2025 pour 24 600 $. Le formulaire 144 exige que le déclarant certifie ne pas détenir d’informations matérielles non divulguées et, s’il s’appuie sur la règle 10b5-1, qu’un plan de négociation conforme existe. Aucun renseignement opérationnel, sur les résultats ou la stratégie n’accompagne cet avis ; il signale uniquement une liquidité interne modeste. Étant donné la taille limitée, les analystes doivent s’attendre à un impact négligeable sur l’offre d’actions ou la valorisation de DNA.

Ginkgo Bioworks Holdings, Inc. (DNA) reichte ein Formular 144 ein, in dem eine geplante Veräußerung von 2.200 Class A Aktien (geschätzter Wert 31.020 USD) über Fidelity Brokerage ab dem 06.08.2025 offengelegt wird. Die Aktien, erworben durch Restricted-Stock-Vesting am 17.10.2022, entsprechen etwa 0,005 % der gemeldeten 46,34 Millionen ausstehenden Aktien � ein unerheblicher Anteil am Streubesitz von DNA.

Der Kontoinhaber, Austin Che, hat in den letzten drei Monaten bereits kleine 99-Aktien-Lose verkauft, insgesamt 3.366 Aktien für etwa 27.000 USD sowie einen Block von 2.200 Aktien am 09.07.2025 für 24.600 USD. Formular 144 verlangt vom Einreicher die Bestätigung, keine nicht offengelegten wesentlichen Informationen zu besitzen und, falls auf Regel 10b5-1 gestützt, dass ein konformer Handelsplan besteht. Es werden keine operativen, Gewinn- oder strategischen Daten mit der Mitteilung übermittelt; sie signalisiert lediglich eine moderate Insider-Liquidität. Aufgrund der begrenzten Größe sollten Analysten mit vernachlässigbarem Einfluss auf das Aktienangebot oder die Bewertung von DNA rechnen.

Positive
  • None.
Negative
  • Ongoing insider selling, albeit small, could slightly dampen investor sentiment if viewed as lack of confidence.

Insights

TL;DR: 2,200-share Form 144 adds to recent small insider sales; size trivial, market impact minimal, sentiment marginally negative.

The filing shows another incremental sale by insider Austin Che, bringing three-month disclosed sales to roughly 5,566 shares. At today’s price, gross proceeds remain well below $100 k, dwarfed by DNA’s multi-billion-share float. Such activity is typical liquidity, not an outright exit, and aligns with shares received via compensation. No new information on fundamentals or guidance is provided. While serial insider selling can weigh on investor sentiment, the microscopic percentage sold and transparent Rule 144 notice render the event neutral from a valuation standpoint.

Ginkgo Bioworks Holdings, Inc. (DNA) ha presentato un modulo Form 144 per comunicare una prevista cessione di 2.200 azioni di Classe A (valore stimato 31.020 dollari) tramite Fidelity Brokerage a partire dal 06/08/2025. Le azioni, ottenute con il vesting di azioni vincolate il 17/10/2022, rappresentano circa lo 0,005% delle 46,34 milioni di azioni in circolazione, una quota irrilevante del flottante di DNA.

Il titolare del conto, Austin Che, ha già venduto piccoli lotti da 99 azioni negli ultimi tre mesi, per un totale di 3.366 azioni per circa 27.000 dollari, oltre a un blocco di 2.200 azioni il 09/07/2025 per 24.600 dollari. Il modulo 144 richiede al dichiarante di certificare di non possedere informazioni materiali non divulgate e, se si basa sulla Regola 10b5-1, che esista un piano di trading conforme. Nessun dato operativo, sugli utili o strategico accompagna la comunicazione; segnala solo una modesta liquidità interna. Data la dimensione limitata, gli analisti dovrebbero aspettarsi un impatto trascurabile sull’offerta di azioni o sulla valutazione di DNA.

Ginkgo Bioworks Holdings, Inc. (DNA) presentó un Formulario 144 divulgando una disposición planificada de 2.200 acciones Clase A (valor estimado en $31,020) a través de Fidelity Brokerage a partir del 06/08/2025. Las acciones, adquiridas mediante vesting de acciones restringidas el 17/10/2022, representan aproximadamente el 0,005% de las 46,34 millones de acciones en circulación, una porción insignificante del flotante de DNA.

El titular de la cuenta, Austin Che, ya ha vendido pequeños lotes de 99 acciones en los últimos tres meses, totalizando 3.366 acciones por alrededor de $27,000, además de un bloque de 2.200 acciones el 09/07/2025 por $24,600. El Formulario 144 requiere que el declarante certifique no poseer información material no divulgada y, si se basa en la Regla 10b5-1, que exista un plan de trading conforme. No se acompañan datos operativos, de ganancias o estratégicos; solo señala una modesta liquidez interna. Dado el tamaño limitado, los analistas deberían esperar un impacto insignificante en la oferta de acciones o valoración de DNA.

Ginkgo Bioworks Holdings, Inc. (DNA)� 2025� 8� 6일부� Fidelity Brokerage� 통해 2,200� 클래� A 주식 (추정 가� 31,020달러)� 처분 계획� 공개하는 Form 144� 제출했습니다. � 주식들은 2022� 10� 17� 제한 주식 베스팅을 통해 취득� 것으�, � 4,634� � � � 0.005%� 해당하는 매우 미미� 규모입니�.

계좌 보유� Austin Che� 지� 3개월� 소규� 99� 단위� � 3,366�� � 27,000달러� 매도했으�, 2025� 7� 9일에� 2,200� 블록� � 24,600달러� 매도했습니다. Form 144� 신고자가 미공� 중요 정보� 보유하지 않았음을 증명하고, Rule 10b5-1� 의거� 경우 적법� 거래 계획� 있음� 확인하도� 요구합니�. 운영, 수익 또는 전략 관� 데이터는 포함되어 있지 않으�, 단지 소규� 내부 유동성을 알리� 공지입니�. 규모가 제한적이므� 애널리스트들은 DNA 주식 공급이나 가치에 거의 영향� 없을 �으로 예상해야 합니�.

Ginkgo Bioworks Holdings, Inc. (DNA) a déposé un formulaire 144 divulguant une cession prévue de 2 200 actions de classe A (valeur estimée à 31 020 $) via Fidelity Brokerage à partir du 06/08/2025. Les actions, acquises par acquisition d’actions restreintes le 17/10/2022, représentent environ 0,005 % des 46,34 millions d’actions en circulation, une part négligeable du flottant de DNA.

Le titulaire du compte, Austin Che, a déjà vendu de petits lots de 99 actions au cours des trois derniers mois, totalisant 3 366 actions pour environ 27 000 $, ainsi qu’un bloc de 2 200 actions le 09/07/2025 pour 24 600 $. Le formulaire 144 exige que le déclarant certifie ne pas détenir d’informations matérielles non divulguées et, s’il s’appuie sur la règle 10b5-1, qu’un plan de négociation conforme existe. Aucun renseignement opérationnel, sur les résultats ou la stratégie n’accompagne cet avis ; il signale uniquement une liquidité interne modeste. Étant donné la taille limitée, les analystes doivent s’attendre à un impact négligeable sur l’offre d’actions ou la valorisation de DNA.

Ginkgo Bioworks Holdings, Inc. (DNA) reichte ein Formular 144 ein, in dem eine geplante Veräußerung von 2.200 Class A Aktien (geschätzter Wert 31.020 USD) über Fidelity Brokerage ab dem 06.08.2025 offengelegt wird. Die Aktien, erworben durch Restricted-Stock-Vesting am 17.10.2022, entsprechen etwa 0,005 % der gemeldeten 46,34 Millionen ausstehenden Aktien � ein unerheblicher Anteil am Streubesitz von DNA.

Der Kontoinhaber, Austin Che, hat in den letzten drei Monaten bereits kleine 99-Aktien-Lose verkauft, insgesamt 3.366 Aktien für etwa 27.000 USD sowie einen Block von 2.200 Aktien am 09.07.2025 für 24.600 USD. Formular 144 verlangt vom Einreicher die Bestätigung, keine nicht offengelegten wesentlichen Informationen zu besitzen und, falls auf Regel 10b5-1 gestützt, dass ein konformer Handelsplan besteht. Es werden keine operativen, Gewinn- oder strategischen Daten mit der Mitteilung übermittelt; sie signalisiert lediglich eine moderate Insider-Liquidität. Aufgrund der begrenzten Größe sollten Analysten mit vernachlässigbarem Einfluss auf das Aktienangebot oder die Bewertung von DNA rechnen.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many Ginkgo Bioworks (DNA) shares are being registered for sale?

The Form 144 covers 2,200 Class A shares, valued at roughly $31,020.

Who is the insider selling DNA shares and when were they acquired?

The proposed seller is Austin Che; the shares vested as restricted stock on 10/17/2022.

When is the expected sale date for the DNA shares?

The filing lists an approximate sale date of 08/06/2025.

What percentage of DNA’s outstanding shares does the sale represent?

The 2,200 shares equal about 0.005 % of the reported 46.34 million shares outstanding.

Is the seller relying on a Rule 10b5-1 trading plan?

The form allows reliance on Rule 10b5-1; by signing, the seller certifies any such plan complies, though no specific date was disclosed.

Have there been other recent insider sales at Ginkgo Bioworks?

Yes. Over the past three months, Che disclosed multiple 99-share trades totaling 3,366 shares plus a 2,200-share block on 07/09/2025.
Ginkgo Bioworks Holdings Inc

NYSE:DNA

DNA Rankings

DNA Latest News

DNA Latest SEC Filings

DNA Stock Data

835.84M
54.73M
6.88%
78.51%
17.67%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
BOSTON